Crinetics Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Crinetics Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.04M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $4.01M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $4.74M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $1.08M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $71.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.19M | Mar 30, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.01M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $71.0K | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $321.0K | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | $505.0K | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | $367.0K | Mar 9, 2020 |
| FY2019 | Dec 31, 2018 | $781.0K | Mar 9, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($465.32M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($298.41M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($214.53M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($163.92M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($107.64M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($73.81M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($14.55M) | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | ($14.43M) | Mar 9, 2020 |
| FY2019 | Jun 30, 2019 | ($12.43M) | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | ($9.02M) | Mar 9, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($516.77M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($338.85M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($222.61M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($167.88M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($107.70M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($74.95M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($53.83M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($28.71M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($9.13M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($6.04M) | Mar 13, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.06M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $240.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $168.53M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $130.23M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $84.26M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $57.00M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $12.14M | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | $11.82M | Mar 9, 2020 |
| FY2019 | Jun 30, 2019 | $10.29M | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | $7.26M | Mar 9, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $99.74M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $58.09M | Feb 26, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($377.92M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($230.19M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($168.60M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($115.21M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($88.59M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($62.03M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($46.38M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($19.46M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($9.48M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($5.47M) | Mar 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.69M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.66M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $436.0K | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $186.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $492.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $1.06M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $304.0K | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $190.0K | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.43B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $635.35M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $352.18M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $351.02M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $183.45M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $130.38M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $171.42M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $15.60M | Mar 13, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.17M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $109.79M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $96.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $35.85M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.07M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $14.53M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $13.24M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $11.19M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $920.0K | Mar 13, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $992.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $539.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $316.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $331.94M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $168.92M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $117.14M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $160.23M | Mar 30, 2022 |
| FY2020 | Dec 31, 2017 | ($15.02M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2016 | ($6.20M) | Mar 9, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.42B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($952.11M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($653.70M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($439.17M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($275.26M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($167.61M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($93.80M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($43.38M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($16.27M) | Mar 13, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $264.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $54.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $32.67M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $200.70M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $93.09M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $40.33M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $44.97M | Mar 30, 2021 |
| FY2018 | Dec 31, 2017 | $14.19M | Mar 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 95.58M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 92.93M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 68.18M | Feb 27, 2025 |
| FY2023 | Aug 31, 2023 | 32.34M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 53.88M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 47.60M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 33.00M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 24.26M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 24,061 | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 1.55M | Mar 13, 2019 |